Patent ID: 9561262
Date: 2017-02-07
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method for treating hypertension in a patient, comprising administering to the patient: a vasoactive intestinal peptide (VIP) having a binding preference for the Vasoactive Intestinal Peptide Receptor 2 (VPAC2), and at least one anti-hypertensive drug selected from a β1 receptor antagonist, an ACE inhibitor, and a calcium channel blocker, wherein the VIP comprises the amino acid sequence of SEQ ID NO: 13 with the N-terminal His at position 2, an N-terminal methionine, and an elastin-like peptide (ELP) at the C-terminus, wherein the ELP comprises at least 90 repeats of VPGXG (SEQ ID NO: 3), wherein the VIP demonstrates an extended half-life in circulation, and wherein the co-administration of the VIP and the anti-hypertensive drug produces a synergistic increase in long-lasting blood pressure control compared to administering VIP alone.